Overview: The Cancer Genomics Consortium (CGC), formerly the Cancer Cytogenomics Microarray Consortium (CCMC), is a not-for-profit organization formed in 2009 by a group of clinical cytogeneticists, molecular pathologists, and molecular geneticists who are interested in applying microarray technologies to cancer diagnosis and cancer research. The mission of the consortium is to promote communication and collaboration among cancer cytogenomics laboratories. CGC goals are to: establish platform-neutral and cancer specific microarray designs for diagnostic purposes; share cancer microarray data between participating institutions for education purposes; create a public cancer array database; and carry out multicenter cancer genome translational research. Collaboration amongst the different laboratories and researchers will not only provide validation for the microarray design(s) but ultimately provide more comprehensive molecular information and more accurate interpretation to better serve cancer patients and further cancer research. The CGC has grown to include more than 300 members from over 150 organizations in the U.S., Canada, and abroad.
Current Status: Active
Last Updated: June 3, 2015